Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822117 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT03822117 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 111 participants.
The verdict
NCT03822117, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.
Interventions
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2022-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822117
The ClinicalTrials.gov registry entry for NCT03822117 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemigatinib is the first listed.
NCT03822117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03822117 about?
NCT03822117 is a clinical study titled "Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)". The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.
What is the current status of trial NCT03822117?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2019-10-17. Estimated completion is 2022-03-29.
What interventions are being tested in trial NCT03822117?
The interventions under investigation include: Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT03822117?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.